Kun Run Biotech came public via a reverse merger on September 16, 2008
Kun Run Biotechnology, Inc., together with its subsidiaries, engages in manufacture and sale of polypeptide medicines. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is 'TP-5' most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia.
Advanced Description :
No additional details have been entered yet. If you would like to moderate the board and provide an advanced description for this stock, please send a Board Moderation Request at top left of board.